Hampus Hillerstrom, Richard Fisher, Matthew P Janicki, Brian Chicoine, Bradley T Christian, Anna Esbensen, Lucille Esralew, Juan Fortea, Sigan Hartley, Jason Hassenstab, Seth M Keller, Sharon Krinsky-McHale, Florence Lai, Johannes Levin, Mary McCarron, Eric McDade, Anne Sophie Rebillat, Herminia Diana Rosas, Wayne Silverman, Andre Strydom, Shahid H Zaman, Henrik Zetterberg
Prior authorization criteria for Federal Drug Administration (FDA) approved immunotherapeutics, among the class of anti-amyloid monoclonal antibodies (mAbs), established by state drug formulary committees, are tailored for adults with late-onset Alzheimer's disease. This overlooks adults with Down syndrome (DS), who often experience dementia at a younger age and with different diagnostic assessment outcomes. This exclusion may deny DS adults access to potential disease-modifying treatments. To address this issue, an international expert panel convened to establish adaptations of prescribing criteria suitable for DS patients and parameters for access to Centers for Medicare & Medicaid Services (CMS) registries...
March 13, 2024: Alzheimer's & Dementia: the Journal of the Alzheimer's Association